

BIOGRAPHICAL SKETCH

NAME Sudhir Srivastava	POSITION TITLE Chief, Cancer Biomarkers Research Group National Cancer Institute, National Institutes of Health Bethesda, MD, USA		
CURRENT AFFILIATION Division of Cancer Prevention, NCI			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Banaras Hindu University	Ph.D.	1977	Protein Changes in Aging
Virginia Commonwealth University	M.S.	1987	Computer Science
Johns Hopkins University	MPH	1997	Public Health Management

List of five recent publications by the candidate:

Srivastava S (2011) State-of-the-Science in Cancer Biomarkers: Principles in Development and Validation. *Advances in Dental research*, April 2011 (in press)

Srivastava S and Krueger K (2011) A Systems Approach to Biomarker Discovery and Validation, book chapter

Claire S. Zhu, Paul F. Pinsky, Daniel W. Cramer, David F. Ransohoff, Patricia Hartge, Ruth M. Pfeiffer, Nicole Urban, Gil Mor, Robert C. Bast, Jr., Lee E. Moore, Anna E. Lokshin, Martin W. McIntosh, Steven J. Skates, Allison Vitonis, Zhen Zhang, David C. Ward, James T. Symanowski, Aleksey Lomakin, Eric T. Fung, Patrick M. Sluss, Nathalie Scholler, Karen H. Lu, Adele M. Marrangoni, Christos Patriotis, Sudhir Srivastava, Sandra S. Buys, and Christine D. Berg for the PLCO Project Team (2010) *Cancer Prevention Research* (2011, in press)

Daniel W. Cramer, Robert C. Bast, Jr., Christine D. Berg, Andrew K. Godwin, Patricia Hartge, Anna E. Lokshin, Karen H. Lu, Martin W. McIntosh, Gil Mor, Christos Patriotis, Paul F. Pinsky, Mark D. Thornquist, Nathalie Scholler, Steven J. Skates, Patrick M. Slus, Sudhir Srivastava, David C. Ward, Zhen Zhang, Claire S. Zhu, Nicole Urban (2010). Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. *Cancer Prevention Research* (2011, in press)

Atha DH, Manne U, Grizzle WE, Wagner PD, Srivastava S and Reipa V (2010). Standards for Immunohistochemical Imaging: A Protein reference device for Biomarker Quantitation, *J. Histochemistry* (in press)

Please indicate in 200 words or less the reason(s) why you would be a suitable candidate for the HUPO Council elections.

Dr. Srivastava is chief of the Cancer Biomarkers Research Group at the NCI. Dr. Srivastava received degrees in biological science (Ph.D.), Computer Science (M.S.) and Public health (MPH). He did postdoctoral studies at Osaka University; the University of California at San Francisco; and the University of Arizona, Tucson. Since 1988, he has served as a program director and focused his responsibility in developing national and international programs in genomics, proteomics, epigenomics, and metabolomics with primary emphasis on cancer screening, early detection, risk assessment and informatics.

Dr. Srivastava has received several honors and awards and is a member of several scientific committees (AJCC, AACR, All Ireland-NCI Consortium). Dr. Srivastava is a founding member of HUPO and has since actively participated in the Plasma Proteome and the Liver Proteome Projects, and supported several HUPO-supported initiatives. He is the principal architect of the NCI's Early Detection Research Network, which

supported a first-ever joint meeting of EDRN-PPP and Proteomics Jamboree. He has actively participated in framing the Human Proteome Project and is a co-author on the pending manuscript. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. Recently, he edited a book on Informatics in Proteomics published by Francis and Taylor, New York. If elected to the HUPO Council, Dr. Srivastava is a thought leader and respected by the scientific community for his acumen, diligence and proactive ideas. Dr. Srivastava will continue to work to strengthen clinical, epidemiological and health care perspectives of proteomics and forge partnerships with public and private sectors. His election to the board will bring credence to the field of translational proteomics research into clinics, the community he represents very well.